Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q96GW9
UPID:
SYMM_HUMAN
Alternative names:
Methionyl-tRNA synthetase 2; Mitochondrial methionyl-tRNA synthetase
Alternative UPACC:
Q96GW9; A0AVC3; Q76E79; Q8IW62; Q8N7N4
Background:
Methionine--tRNA ligase, mitochondrial, also known as Methionyl-tRNA synthetase 2, plays a crucial role in protein synthesis by charging tRNAs with methionine. This enzyme is pivotal for mitochondrial function and overall cellular health.
Therapeutic significance:
Linked to Spastic ataxia 3, autosomal recessive, and Combined oxidative phosphorylation deficiency 25, Methionine--tRNA ligase's dysfunction underscores its potential as a therapeutic target. Understanding its role could lead to novel treatments for these mitochondrial disorders.